Alzheimer’s disease

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Biohaven's Troriluzole Dwindles Again In Alzheimer’s After Anxiety  Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, Troriluzole. The company has tested the efficacy of the drug in more than one indication, including generalized anxiety disorder (GAD), obsessive-compulsive di...

Pfizer's COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, the pharma titan, Pfizer, announced that its COVID-19 vaccine is more than 90% effective in preventing coronavirus infection. Tedros Adhanom Ghebrey...

Neurodegenerative diseases affect millions of people worldwide. And with the world demographics getting older, it is apt to foretell that the burden of neurodegenerative disorders is expected to mount. With advances in medical technology, the life expectancy of people has drastically increased, reeling people to an...

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...

Alzheimer's Disease Market finally witnessed the approval of standard therapy, Aducanumab, by Biogen. What impact does it hold for the future? Demographic or population ageing is a global and dominant phenomenon of the 21st century. Different geographies are experiencing population ageing at different rates. As ...

Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer's disease called futility analysis. The drug was designed to help patients struggling with mild cognitive impairmen...

World Alzheimer’s Day World Alzheimer’s Day takes place on 21 September of every year. World Alzheimer's Day is a campaign to raise awareness and highlight issues faced by people those who are affected by dementia. The exact cause of Alzheimer's disease is not known, although several things are considered to ...

Alzheimer is known to affect an estimated 50 million people worldwide. There is no doubt that this number is going to reach 75 million in 2030 and 131.5 million in 2050 of all age group worldwide. Among affected 5.5 million people aged 65 and older with Alzheimer's in the United States, 3.4 million were reported wo...

Dementia is an umbrella term, usually of a chronic or progressive nature, causing deterioration in cognitive function. Associated with memory loss and decline other in other thinking skills, it is just not restricted to that. Problems with language, decision making, judgement, abstract thinking, struggling in takin...